<body style="display:table; border-collapse:separate; border-spacing:10px;"><div class="separation" id="current" style="display: table-cell; padding: 10px; border: 3px; border-style: solid; border-color: #bbbbbb;"><table class="info">
<tr>
<th nowrap="">ClinicalTrials Identifier:</th><td>NCT00000193</td>
</tr>
<tr>
<th>Updated:</th><td>2013_09_26</td>
</tr>
<tr>
<th class="section" colspan="2">
<h2>Descriptive Information</h2>
</th>
</tr>
<tr>
<th>Brief title</th><td>
<p>Neurobiology of Opioid Dependence: 2 - 2</p>
</td>
</tr>
<tr>
<th>Official title</th><td>
<p>Neurobiology of Opioid Dependence: 2</p>
</td>
</tr>
<tr>
<th>Brief summary</th>
</tr>
<tr>
<td class="bigdent" colspan="2">
<p>The purpose of this study is to evaluate the effects of gamma hydroxybutyric on naloxone-precipitated opiate withdrawal.</p>
</td>
</tr>
<tr>
<th>Detailed description</th>
</tr>
<tr>
<td class="bigdent" colspan="2">
<p></p>
</td>
</tr>
<tr>
<th>Phase</th><td>Phase 2</td>
</tr>
<tr>
<th>Study type</th><td>Interventional</td>
</tr>
<tr>
<th>Study design</th><td>Treatment</td>
</tr>
<tr>
<th>Study design</th><td>Double Blind</td>
</tr>
<tr>
<th>Primary outcome</th><td>Measure: Behavioral, subjective, measures of naloxone-preci</td>
</tr>
<tr>
<th>Primary outcome</th><td>Measure: Phsyiological, neuroendocrine measures of naloxone</td>
</tr>
<tr>
<th>Condition</th><td>
         Opioid-Related Disorders
      </td>
</tr>
<tr>
<th>Intervention</th><td>
<div>Drug: Gamma hydroxybutyric</div>
<p></p>
</td>
</tr>
<tr>
<th>Reference</th><td>
<div>Citation: Neuropsychopharmacology, 1996; 14(3) pp 187-193. Neruopsychopharmacology 1996; 14(3), 187-193</div>
<div>MEDLINE: </div>
</td>
</tr>
<tr>
<th class="section" colspan="2">
<h2>Recruitment Information</h2>
</th>
</tr>
<tr>
<th>Status</th><td>Withdrawn</td>
</tr>
<tr>
<th>Start date</th><td>
         1993-01
      </td>
</tr>
<tr>
<th>Last follow-up date</th><td>
         1998-01
      
      (Actual)
  </td>
</tr>
<tr>
<th>Primary completion date</th><td>
         1998-01
      
      (Actual)
  </td>
</tr>
<tr>
<th>Criteria</th>
</tr>
<tr>
<td class="bigdent" colspan="2">
<p>Please contact site for information.</p>
</td>
</tr>
<tr>
<th>Gender</th><td>
            Male
         </td>
</tr>
<tr>
<th>Healthy volunteers</th><td>No</td>
</tr>
<tr>
<th class="section" colspan="2">
<h2>Administrative Data</h2>
</th>
</tr>
<tr>
<th>Organization name</th><td>Yale University</td>
</tr>
<tr>
<th>Organization study ID</th><td>NIDA-00191-2</td>
</tr>
<tr>
<th>Secondary ID</th><td>K20DA000191
      (US NIH Grant Number)
    </td>
</tr>
<tr>
<th>Secondary ID</th><td>
            K20-00191-2
         </td>
</tr>
<tr>
<th>Sponsor</th><td>
               Yale University
            </td>
</tr>
<tr>
<th>Collaborator</th><td>
               National Institute on Drug Abuse (NIDA)
            </td>
</tr>
<tr>
<th>Collaborator</th><td>
               Yale University
            </td>
</tr>
<tr>
<th>Health Authority</th><td>
               United States: Federal Government
         </td>
</tr>
</table></div><div class="separation" id="past" style="display: table-cell; padding: 10px; border: 3px; border-style: solid; border-color: #bbbbbb;"><html><body><span>&lt;table class="info"&gt;<br/>&lt;tr&gt;<br/>&lt;th nowrap=""&gt;ClinicalTrials Identifier:&lt;/th&gt;&lt;td&gt;NCT00000193&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Updated:&lt;/th&gt;&lt;td&gt;20</span><del style="background:#ffe6e6;">05_12_08</del><ins style="background:#e6ffe6;">13_09_26</ins><span>&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th class="section" colspan="2"&gt;<br/>&lt;h2&gt;Descriptive Information&lt;/h2&gt;<br/>&lt;/th&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Brief title&lt;/th&gt;&lt;td&gt;<br/>&lt;p&gt;Neurobiology of Opioid Dependence: 2 - 2&lt;/p&gt;<br/>&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Official title&lt;/th&gt;&lt;td&gt;<br/>&lt;p&gt;Neurobiology of Opioid Dependence: 2&lt;/p&gt;<br/>&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Brief summary&lt;/th&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;td class="bigdent" colspan="2"&gt;<br/>&lt;p&gt;The purpose of this study is to evaluate the effects of gamma hydroxybutyric on naloxone-precipitated opiate withdrawal.&lt;/p&gt;<br/>&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Detailed description&lt;/th&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;td class="bigdent" colspan="2"&gt;<br/>&lt;p&gt;&lt;/p&gt;<br/>&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Phase&lt;/th&gt;&lt;td&gt;Phase 2&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Study type&lt;/th&gt;&lt;td&gt;Interventional&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Study design&lt;/th&gt;&lt;td&gt;Treatment&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Study design&lt;/th&gt;&lt;td&gt;Double Blind&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/></span><del style="background:#ffe6e6;">&lt;th&gt;Study design&lt;/th&gt;&lt;td&gt;Placebo Control&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/></del><span>&lt;th&gt;Primary outcome&lt;/th&gt;&lt;td&gt;Measure: </span><del style="background:#ffe6e6;"><br/> </del><span>Behavioral, subjective, measures of naloxone-preci</span><del style="background:#ffe6e6;"><br/> </del><span>&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Primary outcome&lt;/th&gt;&lt;td&gt;Measure: </span><del style="background:#ffe6e6;"><br/> </del><span>Phsyiological, neuroendocrine measures of naloxone</span><del style="background:#ffe6e6;"><br/> </del><span>&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Condition&lt;/th&gt;&lt;td&gt;<br/>         Opioid-Related Disorders<br/>      &lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Intervention&lt;/th&gt;&lt;td&gt;<br/>&lt;div&gt;Drug: Gamma hydroxybutyric&lt;/div&gt;<br/></span><ins style="background:#e6ffe6;">&lt;p&gt;&lt;/p&gt;<br/></ins><span>&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Reference&lt;/th&gt;&lt;td&gt;<br/>&lt;div&gt;Citation: Neuropsychopharmacology, 1996; 14(3) pp 187-193. Neruopsychopharmacology 1996; 14(3), 187-193&lt;/div&gt;<br/>&lt;div&gt;MEDLINE: &lt;/div&gt;<br/>&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th class="section" colspan="2"&gt;<br/>&lt;h2&gt;Recruitment Information&lt;/h2&gt;<br/>&lt;/th&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Status&lt;/th&gt;&lt;td&gt;</span><del style="background:#ffe6e6;"><br/>            Completed<br/> </del><ins style="background:#e6ffe6;">Withdrawn</ins><span>&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Start date&lt;/th&gt;&lt;td&gt;<br/>         199</span><del style="background:#ffe6e6;">6</del><ins style="background:#e6ffe6;">3</ins><span>-01<br/>      &lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Last </span><del style="background:#ffe6e6;">data entry</del><ins style="background:#e6ffe6;">follow-up date&lt;/th&gt;&lt;td&gt;<br/>         1998-01<br/> <br/>      (Actual)<br/>  &lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Primary completion</ins><span> date&lt;/th&gt;&lt;td&gt;<br/>         199</span><del style="background:#ffe6e6;">6-10</del><ins style="background:#e6ffe6;">8-01</ins><span><br/> </span><ins style="background:#e6ffe6;"><br/>      (Actual)<br/> </ins><span>&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Criteria&lt;/th&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;td class="bigdent" colspan="2"&gt;<br/>&lt;p&gt;Please contact site for information.&lt;/p&gt;<br/>&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Gender&lt;/th&gt;&lt;td&gt;<br/>            Male<br/>         &lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;</span><del style="background:#ffe6e6;">Minimum age&lt;/th&gt;&lt;td&gt;N/A&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Maximum age&lt;/th&gt;&lt;td&gt;N/A&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Healthy volunteers&lt;/th&gt;&lt;td&gt;No&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Expected enrollment&lt;/th&gt;&lt;td&gt;0</del><ins style="background:#e6ffe6;">Healthy volunteers&lt;/th&gt;&lt;td&gt;No</ins><span>&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th class="section" colspan="2"&gt;<br/>&lt;h2&gt;Administrative Data&lt;/h2&gt;<br/>&lt;/th&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Organization name&lt;/th&gt;&lt;td&gt;</span><del style="background:#ffe6e6;">National Institute on Drug Abuse (NIDA)</del><ins style="background:#e6ffe6;">Yale University</ins><span>&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Organization study ID&lt;/th&gt;&lt;td&gt;NIDA-00191-2&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Secondary ID&lt;/th&gt;&lt;td&gt;</span><ins style="background:#e6ffe6;">K20DA000191<br/>      (US NIH Grant Number)<br/>    &lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Secondary ID&lt;/th&gt;&lt;td&gt;</ins><span><br/></span><del style="background:#ffe6e6;"> </del><span> </span><ins style="background:#e6ffe6;"> </ins><span>K20-00191-2<br/>         &lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Sponsor&lt;/th&gt;&lt;td&gt;<br/></span><ins style="background:#e6ffe6;">               Yale University<br/>            &lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Collaborator&lt;/th&gt;&lt;td&gt;<br/></ins><span>               National Institute on Drug Abuse (NIDA)<br/>            &lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Collaborator&lt;/th&gt;&lt;td&gt;<br/>               Yale University<br/>            &lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Health Authority&lt;/th&gt;&lt;td&gt;<br/>               United States: Federal Government<br/>         &lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;/table&gt;</span></body></html></div></body>